Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC

Key Points

• UBS AM decreased its holdings in Zimmer Biomet by 2.1%, selling 37,171 shares during the first quarter, leaving them with 1,730,730 shares, valued at approximately $195.88 million.
• Several major institutional investors, including Vanguard Group and JPMorgan Chase, increased their stakes in Zimmer Biomet, reflecting strong interest in the company despite UBS's reduction.
• Zimmer Biomet recently announced a quarterly dividend of $0.24 per share, with a dividend yield of 0.9%, and reported earnings that surpassed analysts’ expectations.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC trimmed its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 2.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,730,730 shares of the medical equipment provider's stock after selling 37,171 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 0.87% of Zimmer Biomet worth $195,884,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Ameriprise Financial Inc. grew its position in shares of Zimmer Biomet by 236.0% during the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider's stock valued at $517,039,000 after buying an additional 3,208,596 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Zimmer Biomet by 251.3% in the first quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider's stock valued at $235,571,000 after acquiring an additional 1,488,918 shares during the period. Nuveen LLC acquired a new position in Zimmer Biomet in the first quarter valued at approximately $155,891,000. Nuveen Asset Management LLC grew its holdings in shares of Zimmer Biomet by 191.8% during the fourth quarter. Nuveen Asset Management LLC now owns 1,389,405 shares of the medical equipment provider's stock valued at $146,763,000 after purchasing an additional 913,310 shares during the last quarter. Finally, Alyeska Investment Group L.P. acquired a new stake in shares of Zimmer Biomet during the 1st quarter worth approximately $101,294,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the transaction, the senior vice president directly owned 6,833 shares of the company's stock, valued at $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.70% of the stock is owned by corporate insiders.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH traded down $1.11 during trading on Friday, reaching $103.15. The company had a trading volume of 883,462 shares, compared to its average volume of 1,177,293. The firm's fifty day moving average is $99.46 and its 200 day moving average is $99.55. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. The firm has a market capitalization of $20.43 billion, a PE ratio of 25.10, a price-to-earnings-growth ratio of 2.37 and a beta of 0.68. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.22 and a twelve month high of $114.72.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts' consensus estimates of $1.98 by $0.09. The business had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter last year, the business earned $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a $0.24 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. Zimmer Biomet's dividend payout ratio is 23.36%.

Analyst Ratings Changes

ZBH has been the subject of a number of analyst reports. Evercore ISI reduced their price objective on Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. UBS Group upped their price target on shares of Zimmer Biomet from $91.00 to $96.00 and gave the stock a "sell" rating in a research report on Friday, August 8th. Roth Capital reissued a "buy" rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. Raymond James Financial upped their target price on shares of Zimmer Biomet from $104.00 to $113.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Finally, Royal Bank Of Canada lifted their price target on Zimmer Biomet from $112.00 to $115.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Nine research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $111.00.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.